keyword
MENU ▼
Read by QxMD icon Read
search

statin + cancer

keyword
https://www.readbyqxmd.com/read/28806117/postdiagnosis-statin-use-and-mortality-in-danish-patients-with-prostate-cancer
#1
Signe Benzon Larsen, Christian Dehlendorff, Charlotte Skriver, Susanne Oksbjerg Dalton, Christina Gade Jespersen, Michael Borre, Klaus Brasso, Mette Nørgaard, Christoffer Johansen, Henrik Toft Sørensen, Jesper Hallas, Søren Friis
Purpose Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark. Material and Methods From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag...
August 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28790158/lung-tumors-with-distinct-p53-mutations-respond-similarly-to-p53-targeted-therapy-but-exhibit-genotype-specific-statin-sensitivity
#2
Frances K Turrell, Emma M Kerr, Meiling Gao, Hannah Thorpe, Gary J Doherty, Jake Cridge, David Shorthouse, Alyson Speed, Shamith Samarajiwa, Benjamin A Hall, Meryl Griffiths, Carla P Martins
Lung adenocarcinoma accounts for ∼40% of lung cancers, the leading cause of cancer-related death worldwide, and current therapies provide only limited survival benefit. Approximately half of lung adenocarcinomas harbor mutations in TP53 (p53), making these mutants appealing targets for lung cancer therapy. As mutant p53 remains untargetable, mutant p53-dependent phenotypes represent alternative targeting opportunities, but the prevalence and therapeutic relevance of such effects (gain of function and dominant-negative activity) in lung adenocarcinoma are unclear...
August 8, 2017: Genes & Development
https://www.readbyqxmd.com/read/28770167/fatal-statin-induced-rhabdomyolysis-by-possible-interaction-with-palbociclib
#3
Kellie Lynn Nelson, David Stenehjem, Meghan Driscoll, Glynn Weldon Gilcrease
A 60- to 65-year-old female on prior statin therapy was initiated on palbociclib and fulvestrant for the treatment of metastatic, hormone-receptor positive breast cancer. She subsequently developed sudden progressive muscle weakness that progressed to death within weeks. The patient noticed progressive proximal muscle weakness after two cycles of palbociclib, with no other medication changes in the interim. This rapidly progressed and resulted in death within 7 days of presentation to hospital. There has been one previous report of rhabdmyolysis with palbociclib, occurring in a patient on concomitant statin...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28769006/mechanistic-study-of-inhibitory-effects-of-metformin-and-atorvastatin-in-combination-on-prostate-cancer-cells-in-vitro-and-in-vivo
#4
Zhen-Shi Wang, Hua-Rong Huang, Lan-Yue Zhang, Seungkee Kim, Yan He, Dong-Li Li, Chelsea Farischon, Kun Zhang, Xi Zheng, Zhi-Yun Du, Susan Goodin
Metformin is a commonly used drug for the treatment of type II diabetes and atorvastatin is the most prescribed cholesterol-lowering statin. The present study investigated the effects and mechanisms of metformin and atorvastatin in combination on human prostate cancer cells cultured in vitro and grown as xenograft tumor in vivo. Metformin in combination with atorvastatin had stronger effects on growth inhibition and apoptosis in PC-3 cells than either drug alone. The combination also potently inhibited cell migration and the formation of tumorspheres...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28762529/the-impact-of-statin-use-on-the-efficacy-of-abiraterone-acetate-in-patients-with-castration-resistant-prostate-cancer
#5
Lauren C Harshman, Lillian Werner, Abhishek Tripathi, Xiaodong Wang, Benjamin L Maughan, Emmanuel S Antonarakis, Mari Nakabayashi, Rana McKay, Mark Pomerantz, Lorelei A Mucci, Mary-Ellen Taplin, Christopher J Sweeney, Gwo-Shu Mary Lee, Philip W Kantoff
BACKGROUND: Statins compete with DHEAS for influx through the SLCO2B1 transporter, which may prolong time to progression (TTP) on androgen deprivation therapy. Abiraterone acetate (AA) may also undergo SLCO-mediated transport. Based on preclinical findings showing antagonism, we hypothesized that statins may compete with AA for influx via SLCO2B1 and could negatively impact drug efficacy. METHODS: We queried two institutional clinical databases (Dana-Farber Cancer Institute [DFCI], Johns Hopkins University [JHU]) for CRPC patients treated with AA...
August 1, 2017: Prostate
https://www.readbyqxmd.com/read/28760843/atorvastatin-enhances-radiosensitivity-of-hypoxia-induced-prostate-cancer-cells-related-with-hif-1%C3%AE-inhibition
#6
Bin Chen, Minguang Zhang, Dongwei Xing, Yu Feng
Background: Hypoxia could enhance radioresistance of prostate cancer cells through up-regulating HIF-1α, which could be inhibited by statins in several cancer cells. However, this effect of statins in prostate cancer remains unclear. In this study, we aim to investigate the effect of atorvastatin on HIF-1αexpression and radiosensitivity of prostate cancers cells.  Methods:The hypoxia-induced human prostate cancer PC3 cells were generated by incubating with 5% O2 for 24 hours. The cell viability and apoptosis were respectively analyzed by cell counting kit-8 (CCK-8) assay and flow cytometry...
July 31, 2017: Bioscience Reports
https://www.readbyqxmd.com/read/28753882/statin-use-and-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-abiraterone-acetate
#7
Giuseppe Di Lorenzo, Guru Sonpavde, Gregory Pond, Giuseppe Lucarelli, Sabrina Rossetti, Gaetano Facchini, Sarah Scagliarini, Giacomo Cartenì, Piera Federico, Bruno Daniele, Franco Morelli, Teresa Bellelli, Matteo Ferro, Sabino De Placido, Carlo Buonerba
BACKGROUND: Although statin use has been associated with favorable effects in various solid malignancies, no conclusive evidence is available at present. Statins are safe and inexpensive, and may synergize with novel antiandrogen agents abiraterone via pharmacokinetic interactions and decrease substrate availability for de novo androgen biosynthesis. OBJECTIVE: To determine whether statin use affects survival in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone...
April 8, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28742648/vitamin-d-deficiency-supplementation-and-cardiovascular-health
#8
Naveen Trehan, Luis Afonso, Diane L Levine, Phillip D Levy
Vitamin D has been traditionally recognized as a vitamin quintessential for bone-mineral health. In the past 2 decades, numerous experimental and observational studies have highlighted the role of vitamin D in immunity, metabolic syndrome (obesity and diabetes), cancers, renal disease, memory, and neurological dysfunction. In this article, we review important studies that focused on the impact of vitamin D on blood pressure, myocardial infarction, peripheral arterial disease, heart failure, and statin intolerance...
September 2017: Critical Pathways in Cardiology
https://www.readbyqxmd.com/read/28729418/myc-regulated-mevalonate-metabolism-maintains-brain-tumor-initiating-cells
#9
Xiuxing Wang, Zhi Huang, Qiulian Wu, Briana C Prager, Stephen C Mack, Kailin Yang, Leo J Y Kim, Ryan C Gimple, Yu Shi, Sisi Lai, Qi Xie, Tyler E Miller, Christopher G Hubert, Anne Song, Zhen Dong, Wenchao Zhou, Xiaoguang Fang, Zhe Zhu, Vaidehi Mahadev, Shideng Bao, Jeremy N Rich
Metabolic dysregulation drives tumor initiation in a subset of glioblastomas harboring isocitrate dehydrogenase (IDH) mutations, but metabolic alterations in glioblastomas with wildtype IDH are poorly understood. MYC promotes metabolic reprogramming in cancer, but targeting MYC has proven notoriously challenging. Here, we link metabolic dysregulation in patient-derived brain tumor initiating cells (BTICs) to a nexus between MYC and mevalonate signaling, which can be inhibited by statin or 6-fluoromevalonate treatment...
July 20, 2017: Cancer Research
https://www.readbyqxmd.com/read/28726527/the-comparison-and-estimation-of-the-prognostic-value-of-lipid-profiles-in-patients-with-prostate-cancer-depends-on-cancer-stage-advancement
#10
Edyta Idalia Wolny-Rokicka, Andrzej Tukiendorf, Jerzy Wydmański, Agnieszka Zembroń-Łacny
Lipid profiles and prostate cancer have a controversial relationship, and the predictive ability of lipids in determining cancer risk estimation is still questionable. This study demonstrates a significance assessment of the plasma lipid profiles of subjects with prostate cancer. Locoregional subjects irradiated with external beam therapy were compared to prostate cancer subjects with bone metastases. The histopathologic diagnosis of 103 subjects (71 locoregional [Group 1] and 32 palliative [Group 2]) were analyzed and compared using their blood samples, total cholesterol (CHL), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol...
July 1, 2017: American Journal of Men's Health
https://www.readbyqxmd.com/read/28720842/pre-diagnostic-statin-use-lymph-node-status-and-mortality-in-women-with-stages-i-iii-breast-cancer
#11
Amelia Smith, Laura Murphy, Lina Zgaga, Thomas I Barron, Kathleen Bennett
BACKGROUND: Recent meta-analyses suggest that pre-diagnostic statin use is associated with reduced breast cancer-specific mortality. Studies have shown that high breast tumour expression of the statin target (3-hydroxy-3-methylglutaryl coenzyme-A reductase) is associated with lymph-node negative cancer. Therefore, we examined the association between pre-diagnostic statin use and; lymph node status, breast cancer-specific and all-cause mortality. METHODS: Women with stages I-III breast cancer were identified from the National Cancer Registry of Ireland (N=6314)...
August 8, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28713941/additive-antitumor-effects-of-celecoxib-and-simvastatin-on-head-and-neck-squamous-cell-carcinoma-in%C3%A2-vitro
#12
Thomas Gehrke, Agmal Scherzad, Stephan Hackenberg, Pascal Ickrath, Philipp Schendzielorz, Rudolf Hagen, Norbert Kleinsasser
Lipid-lowering statins as well as non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to possess cancer-protective effects in many epidemiologic cohort studies. However, the underlying mechanisms of these findings are mostly unknown. To evaluate possible additive antitumor effects of statins and NSAIDs in vitro, PJ-41 and HLaC78 head and neck squamous cell carcinoma cells (HNSCC) were treated with 40 µM celecoxib, 50 µM simvastatin or a combination of both. Analysis of tumor viability, proliferation, apoptosis, cell cycle changes and secretion of interleukin-6 (IL-6) and interleukin-8 (IL-8) was conducted via MTT assay, Annexin V-propidium iodide test, cell cycle analysis, colony assay and enzyme-linked immunosorbent assay (ELISA)...
July 10, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28711915/statin-use-and-endometrial-cancer-risk-a-meta-analysis
#13
Weimin Xie, Qiaoling Zhu, Qiao Liu, Yingxia Wang, Jing Yang, Lili Hu
Several studies have evaluated the association between statin use and endometrial cancer risk. We carried out a meta-analysis of randomized controlled trials (RCTs) and non-randomized studies to evaluate the effect of statins on endometrial cancer risk. A comprehensive search of electronic databases, conference abstracts and clinical trial registers was conducted for published and unpublished results. Studies that evaluated exposure to statins and endometrial cancer risk were considered. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using either a fixed-effects or a random-effects model...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28710496/dietary-geranylgeraniol-can-limit-the-activity-of-pitavastatin-as-a-potential-treatment-for-drug-resistant-ovarian-cancer
#14
Elizabeth de Wolf, Marwan Ibrahim Abdullah, Stefanie M Jones, Karen Menezes, Darren M Moss, Falko P Drijfhout, Sarah R Hart, Clare Hoskins, Euan A Stronach, Alan Richardson
Pre-clinical and retrospective studies of patients using statins to reduce plasma cholesterol have suggested that statins may be useful to treat cancer. However, prospective clinical trials have yet to demonstrate significant efficacy. We have previously shown that this is in part because a hydrophobic statin with a long half-life is necessary. Pitavastatin, the only statin with this profile, has not undergone clinical evaluation in oncology. The target of pitavastatin, hydroxymethylglutarate coenzyme-A reductase (HMGCR), was found to be over-expressed in all ovarian cancer cell lines examined and upregulated by mutated TP53, a gene commonly altered in ovarian cancer...
July 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28700275/guideline-based-statin-eligibility-cancer-events-and-noncardiovascular-mortality-in-the-framingham-heart-study
#15
Amit Pursnani, Joseph M Massaro, Ralph B D'Agostino, Christopher J O'Donnell, Udo Hoffmann
Purpose Cancer and cardiovascular disease share risk factors, and there is some evidence that statins reduce cancer mortality. We sought to determine the accuracy of the 2013 American College of Cardiology/American Heart Association statin eligibility criteria to identify individuals at a higher risk of developing cancer or of dying as a result of cancer or other noncardiovascular causes. Methods We included 2,196 participants (50.5 ± 8.1 years of age; 55% female) who were statin naïve and free of cancer at baseline from the offspring and third-generation cohorts of the community-based longitudinal Framingham Heart Study...
July 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28700151/-common-medications-and-prostate-cancer-what-is-the-association
#16
Arnas Rakauskas, Nuno Grilo, Olivier M'Baya, Patrice Jichlinski, Massimo Valerio, Dominik Berthold
A possible association between prostate cancer and metabolic syndrome has recently been observed. Further, multiple experimental and epidemiologic studies have recently reported a probable association between common medications and prostate cancer. In this article, we summarize the results of those studies that explore the role of aspirin, oral antidiabetic medication and statins.
November 30, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28697149/the-influence-of-statins-on-risk-and-patient-survival-in-colorectal-cancer
#17
Baoge Qu, Hao Qu
No abstract text is available yet for this article.
July 10, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28691139/systematic-review-and-meta-analysis-use-of-statins-is-associated-with-a-reduced-incidence-of-oesophageal-adenocarcinoma
#18
Tom Thomas, Yoon Loke, Ian L P Beales
PURPOSE: Laboratory studies have suggested that statins may have useful anti-cancer effects against Barrett's epithelial cancer lines. A variety of effects have been reported in clinical studies. METHODS: We performed a systematic review and meta-analysis of the association between statin use and the development of oesophageal cancer. Multiple databases were searched for studies reporting the association of statin use and oesophageal cancer. Meta-analysis on the relationship between statin use and cancer incidence was performed...
July 10, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28683466/commonly-used-medications-and-endometrial-cancer-survival-a-population-based-cohort-study
#19
Omolara B Sanni, Úna C Mc Menamin, Chris R Cardwell, Linda Sharp, Liam J Murray, Helen G Coleman
BACKGROUND: Increasing incidence and new indications for existing drugs make it important to identify new adjuvant therapies for endometrial cancer (EC). METHODS: This is a prospective cohort study of 3058 newly diagnosed EC cases from 1998 to 2010, identified through record linkages between the UK Clinical Practice Research Datalink, the National Cancer Research Datalink and death registrations from the Office of National Statistics. Using Cox regression models, unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for EC-specific survival...
July 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28682909/statins-intake-and-risk-of-liver-cancer-a-dose-response-meta-analysis-of-prospective-cohort-studies
#20
Changhong Yi, Zhenggui Song, Maolin Wan, Ya Chen, Xiang Cheng
Previous studies have indicated that statins intake was associated with liver cancer risk, but presented controversial results.Studies in PubMed and EMBASE were searched update to February 2017 to identify and quantify the potential dose-response association between statins intake and liver cancer.Six eligible studies involving a total of 11,8961 participants with 9530 incident cases were included in this meta-analysis. Statistically significant association was observed between increasing statins intake and liver cancer risk reduction (OR = 0...
July 2017: Medicine (Baltimore)
keyword
keyword
23289
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"